Ascletis Pharma Inc. Completes Enrollment in U.S. Phase II Study of ASC30 for Diabetes

Key Highlights

• Ascletis Pharma Inc. has completed enrollment in its pivotal 13-week, U.S.-based Phase II clinical trial for ASC30, an oral small molecule GLP-1 receptor agonist, targeting type 2 diabetes mellitus (T2D).
• This study marks the second clinical indication for ASC30, following promising results in obesity treatment.
• 100 participants with T2D have been enrolled across multiple U.S. sites. Topline results are expected in Q3 2026.

Details of the Study and ASC30’s Potential

The Phase II trial (NCT07321678) is a randomized, double-blind, placebo-controlled, multi-center study designed to evaluate the efficacy, safety, and tolerability of ASC30 tablets for T2D patients. ASC30 is being developed as a once-daily oral therapy, which could provide a significant convenience and compliance advantage compared to current injectable GLP-1 therapies.

ASC30’s primary endpoint is the mean change in HbA1c (a key measure of blood sugar control) from baseline over 13 weeks compared to placebo. Secondary endpoints include changes in fasting blood glucose, body weight, and overall safety and tolerability.

Participants were randomized in a 2:3:3:2 ratio to receive 40 mg, 60 mg, or 80 mg of ASC30, or matching placebo. The dosing regimen involved a weekly titration from 1 mg to the target dose, aimed at maximizing efficacy while minimizing side effects.

Significance for Shareholders

• Market Expansion: ASC30’s move into diabetes follows positive obesity trial data, opening a vast new market opportunity given the size and growth of the diabetes population.
• Pipeline Progression: Based on positive obesity data (announced December 2025), Ascletis expects to obtain U.S. FDA clearance and initiate Phase III trials in obesity by end of Q3 2026. This progression could significantly de-risk the program and attract investor interest.
• Best-in-Class Potential: ASC30 is the first and only investigational small molecule GLP-1R fully biased agonist, with both oral (once daily) and injectable (monthly to quarterly) administration options for metabolic diseases. This dual platform enhances commercial flexibility and market reach.
• Data Catalyst: Topline results from the diabetes Phase II trial are expected in Q3 2026, which could serve as a major price catalyst depending on the outcome.

Management Commentary

Dr. Jinzi Jason Wu, Founder, Chairman, and CEO of Ascletis, emphasized the strategic importance of expanding ASC30 into the diabetes market, stating that this step highlights the candidate’s potential best-in-class profile as a once-daily oral treatment. He noted the robust efficacy and tolerability shown in the obesity Phase II trial, and expressed confidence in the company’s ability to move rapidly towards Phase III trials in obesity, pending regulatory clearance.

Risks & Cautionary Notes

• Investors should be aware that successful development, manufacturing, and commercialization of ASC30 is not guaranteed. The program remains subject to regulatory review and clinical risk.
• Further news flow, especially the anticipated Phase II diabetes data in Q3 2026 and potential FDA clearance for Phase III in obesity, could be material share price movers.

Board Information

As of the announcement date, the Board consists of Dr. Jinzi Jason Wu and Mrs. Judy Hejingdao Wu as executive directors, and Dr. Yizhen Wei, Mr. Jiong Gu, and Ms. Lin Hua as independent non-executive directors.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. Clinical development is subject to significant risks and uncertainties, and investors should consider the inherent risks involved. The company cannot guarantee the successful development, approval, or commercialization of ASC30. Readers are encouraged to consult professional advisors before making investment decisions.

View ASCLETIS-B Historical chart here